RLY-2608 is under clinical development by Relay Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RLY-2608’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RLY-2608 overview

RLY-2608 is under development for the treatment of solid tumors, metastatic breast cancer, HR positive/human epidermal growth factor receptor 2 negative breast cancer (HER2- Breast Cancer). It is administered through oral route. It is a small molecule and acts by targeting H1047X, E542X and E545X mutant phosphoinositide 3-kinase (PI3K). The drug candidate is being developed based on dynamo platform.

Relay Therapeutics overview

Relay Therapeutics is a biotechnology company that develops therapies for multiple diseases. The company’s technology enables the rational allosteric drug discovery process to design better drugs. It leverages insights from protein motion to develop its products. Relay Therapeutics brings together scientific advances including biophysics, chemistry, structural biology, computation, and biology to enable new approaches for therapeutic intervention in disease. Its research focuses on the discovery and development of oncology therapeutics. The company partners with various healthcare companies. Relay Therapeutics is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of RLY-2608’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.